Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity
Joint Authors
Zhang, Yuan
Wu, Jing
Zhao, Fei
Xue, Jiang
Kuang, Jiangying
Jin, Zhi
Zhang, Taie
Jiang, Chunjie
Wang, Dingding
Liang, Shuang
Source
Issue
Vol. 2020, Issue 2020 (31 Dec. 2020), pp.1-8, 8 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2020-02-20
Country of Publication
Egypt
No. of Pages
8
Main Subjects
Abstract EN
It has been recognized that people with obesity are more likely to have low growth hormone secretion.
Recent studies have also confirmed that the abnormalities of the growth hormone/insulin-like growth factor 1 axis were associated with cardiovascular complications in people with obesity.
However, little is known about whether recombinant human growth hormone therapy could improve cardiovascular and metabolic risks in obese children.
This study aims to evaluate the effect of one-year growth hormone therapy on obesity-related comorbidities and to assess the safety in Chinese boys with obesity.
Eighteen boys with obesity were treated with recombinant human growth hormone for one year.
Anthropometric measurements, endocrine testing, and cardiovascular risk markers were performed in all obese boys in baseline, and follow-up visits were performed at 3 months, 6 months, 9 months, and one year, respectively.
After one year of recombinant human growth hormone treatment, the body mass index standard deviation scores decreased (P<0.001) and insulin-like growth factor 1 levels increased (P<0.001).
GH treatment also reduced low density lipoprotein cholesterol (P<0.001), total cholesterol (P<0.001), triglycerides (P=0.042), and alanine aminotransferase (P=0.027) when compared with the baseline.
One-year of recombinant human growth hormone treatment could improve cardiometabolic risk markers, without adverse effects on glucose homeostasis in boys with obesity.
American Psychological Association (APA)
Wu, Jing& Zhao, Fei& Zhang, Yuan& Xue, Jiang& Kuang, Jiangying& Jin, Zhi…[et al.]. 2020. Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity. BioMed Research International،Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1132416
Modern Language Association (MLA)
Wu, Jing…[et al.]. Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity. BioMed Research International No. 2020 (2020), pp.1-8.
https://search.emarefa.net/detail/BIM-1132416
American Medical Association (AMA)
Wu, Jing& Zhao, Fei& Zhang, Yuan& Xue, Jiang& Kuang, Jiangying& Jin, Zhi…[et al.]. Effect of One-Year Growth Hormone Therapy on Cardiometabolic Risk Factors in Boys with Obesity. BioMed Research International. 2020. Vol. 2020, no. 2020, pp.1-8.
https://search.emarefa.net/detail/BIM-1132416
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1132416